Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

Reck, M; Ciuleanu, T-E; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Sakai, H; Lingua, A; Reyes, F; Souquet, P-J; De Marchi, P; Martin, C; Pérol, M; Scherpereel, A; Lu, S; Paz-Ares, L; Carbone, D P; Memaj, A; Marimuthu, S; Zhang, X; Tran, P; John, Thomas

doi:10.1016/j.esmoop.2021.100345

Austin Health

Title

Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

Publication Date

2021-12-02

Author(s)

Reck, M

Ciuleanu, T-E

Cobo, M

Schenker, M

Zurawski, B

Menezes, J

Richardet, E

Bennouna, J

Felip, E

Juan-Vidal, O

Alexandru, A

Sakai, H

Lingua, A

Reyes, F

Souquet, P-J

De Marchi, P

Martin, C

Pérol, M

Scherpereel, A

Lu, S

Paz-Ares, L

Carbone, D P

Memaj, A

Marimuthu, S

Zhang, X

Tran, P

John, Thomas

Type of document

Journal Article

DOI

10.1016/j.esmoop.2021.100345

Link

link

Citation

ESMO Open 2021; 6(6): 100345

Jornal Title

ESMO Open

Files:

Name	Size	format	Description	Link